KRAS and acute myeloid leukemia: SLC22A3 hypermethylation was associated with lower platelets and higher CEBPA mutation rate in non-APL AML patients (P = 0.020 and 0.006), as well as higher mutation rate of N/K-RAS in CN-AML (P = 0.080; Table 1).